PharmaCyte Biotech
PMCB
PMCB
25 hedge funds and large institutions have $8.83M invested in PharmaCyte Biotech in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
4% less funds holding
Funds holding: 26 → 25 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Holders
25
Holding in Top 10
1
Calls
$207K
Puts
$158K
Top Buyers
| 1 | +$649K | |
| 2 | +$202K | |
| 3 | +$135K | |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$133K |
| 5 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
+$116K |
Top Sellers
| 1 | -$484K | |
| 2 | -$35K | |
| 3 | -$26K | |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$23.3K |
| 5 |
Morgan Stanley
New York
|
-$14.4K |